Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

94.68USD
21 Nov 2017
Change (% chg)

$1.08 (+1.15%)
Prev Close
$93.60
Open
$93.75
Day's High
$95.40
Day's Low
$93.61
Volume
1,158,575
Avg. Vol
1,619,391
52-wk High
$98.20
52-wk Low
$58.61

Select another date:

Tue, Nov 21 2017

Roche, AbbVie leukemia drug superior to older medicine in study

Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

Roche, AbbVie leukemia drug superior to older medicine in study

Nov 21 Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

BRIEF-AbbVie, on conf call, says we need to see HCV market sort itself out

* AbbVie CEO, on conf call, says we need to see HCV market sort itself out

AbbVie says Humira sales will balloon to $21 billion in 2020, shares rise

AbbVie Inc forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago, driving the U.S. drugmaker's shares up 4 percent on Friday.

UPDATE 2-AbbVie says Humira sales will balloon to $21 bln in 2020, shares rise

* Shares up 4 percent (Adds analyst comment, updates share price)

BRIEF-Abbvie increases quarterly dividend by 11 percent

* Sets quarterly cash dividend of $0.71 per share Source text for Eikon: Further company coverage:

AbbVie says Humira sales will balloon to $21 bln in 2020

Oct 27 AbbVie Inc on Friday forecast its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.

BRIEF-Abbvie receives U.S. FDA priority review for investigational Oral Treatment Elagolix

* Abbvie receives U.S. FDA priority review for Investigational Oral Treatment Elagolix for the management of Endometriosis with associated pain

BRIEF-AbbVie says ‍Health Canada approved inclusion of nail Psoriasis data in humira product monograph​

* AbbVie Inc says ‍Health Canada has approved inclusion of Nail Psoriasis data in Humira product monograph​ Source text for Eikon: Further company coverage:

AbbVie bets on Alzheimer's immunotherapy with big biotech deal

U.S. drugmaker AbbVie is betting on the potential of the body's immune system to fight Alzheimer's by signing a drug development deal worth more than $200 million with unlisted biotech company Alector.

Select another date: